Stockreport

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Insight Molecular Diagnostics Inc.  (IMDX) 
PDF On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of [Read more]